Greater Glasgow and Clyde Medicines
Key to symbols The medicine should be initiated by, or on the advice of a specialist, but is suitable for continuation by a GP The medicine should only be used and prescribed by a specialist Indicates the preferred choice within a class or group of medicines
The medicine should be initiated by, or on the advice of a specialist, but is suitable for continuation by a GP
The medicine should only be used and prescribed by a specialist
Indicates the preferred choice within a class or group of medicines
9.1. Anaemias and some other blood disorders

9.1.8. Drugs for other blood disorders

Total Formulary
Specialist Only
CROVALIMAB (PIASKY)

Restrictions:

Restricted to use under the advice of the national paroxysmal nocturnal haemoglobinuria (PNH) service as monotherapy for the treatment of adult and paediatric patients 12 years of age or older with a weight of 40 kg and above with PNH:

  • In patients with haemolysis with clinical symptom(s) indicative of high disease activity.
  • In patients who are clinically stable after having been treated with a complement component 5 (C5) inhibitor for at least the past 6 months.

BNF Link

Specialist Only
DANICOPAN (VOYDEYA)

Restrictions:

Restricted to use under the advice of the national paroxysmal nocturnal haemoglobinuria (PNH) service as add-on to ravulizumab or eculizumab for the treatment of adult patients with PNH who have residual haemolytic anaemia.

BNF Link

Specialist Only
ETRANACOGENE DEZAPARVOVEC (Hemgenix)

Restrictions:

Restricted to specialist use for the treatment of severe and moderately severe haemophilia B (congenital factor IX deficiency) in adult patients without a history of factor IX inhibitors.

BNF Link

Specialist Only
IPTACOPAN (FABHALTA)

Restrictions:

Restricted to use under the advice of the national paroxysmal nocturnal haemoglobinuria (PNH) service as monotherapy in the treatment of adult patients with PNH who have haemolytic anaemia.

BNF Link

Specialist Only
PEGCETACOPLAN (Aspaveli) (sub-cutaneous infusion)

Restrictions:

Restricted to specialist use under the advice of the national PNH Service for patients with paroxysmal nocturnal haemoglobinuria (PNH) who are anaemic after treatment with a C5 inhibitor for at least 3 months.

BNF Link

Specialist Only
RAVULIZUMAB (Ultomiris) (infusion)

Restrictions:

Restricted to specialist use for the following indications:

  • Treatment of adults with paroxysmal nocturnal haemoglobinuria (PNH) on the advice of the national PNH service:
    • in patients with haemolysis with clinical symptom(s) indicative of high disease activity
    • in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months
  • Treatment of patients with atypical haemolytic uremic syndrome (aHUS) under the advice of the National Renal Complement Therapeutics Service (based in Newcastle) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Prescribing Notes:

Non-formulary indications as not recommended by SMC (non-submission):

  • Treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin 4 (AQP4) antibody-positive
  • Add-on to standard therapy for the treatment of adult patients with generalized myasthenia gravis (gMG) who are antiacetylcholine receptor (AChR) antibody-positive

BNF Link